CHINARES PHARMA Considers Divesting Approximately 17.87% Stake in Tianmai Biotech

Stock News

Feb 09

CHINARES PHARMA (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 17.87% of its stake in Hefei Tianmai Biotech Development Co., Ltd. The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a minimum listing price set at approximately RMB 1.42 billion. As of the announcement date, CHINARES PHARMA's subsidiary and its affiliates hold less than a 30% stake in Tianmai Biotech.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1171755274"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171755274\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171755274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171755274","market":"nz","top_or_hot":-1,"title":"CHINARES PHARMA Considers Divesting Approximately 17.87% Stake in Tianmai Biotech","media":"Stock News","content":"<p>CHINARES PHARMA (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 17.87% of its stake in Hefei Tianmai Biotech Development Co., Ltd. The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a minimum listing price set at approximately RMB 1.42 billion. As of the announcement date, CHINARES PHARMA's subsidiary and its affiliates hold less than a 30% stake in Tianmai Biotech.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA Considers Divesting Approximately 17.87% Stake in Tianmai Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA Considers Divesting Approximately 17.87% Stake in Tianmai Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-09 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 17.87% of its stake in Hefei Tianmai Biotech Development Co., Ltd. The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a minimum listing price set at approximately RMB 1.42 billion. As of the announcement date, CHINARES PHARMA's subsidiary and its affiliates hold less than a 30% stake in Tianmai Biotech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1171755274","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171755274","pubTimestamp":1770637814,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 17.87% of its stake in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","BK1191":"制药","LABU":"三倍做多标普生物-Direxion","03320":"华润医药","BK1570":"华润系","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"CHINARES PHARMA考虑剥离天迈生物约17.87%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"LABU":1,"03320":1},"content_text":"CHINARES PHARMA (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 17.87% of its stake in Hefei Tianmai Biotech Development Co., Ltd. The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a minimum listing price set at approximately RMB 1.42 billion. As of the announcement date, CHINARES PHARMA's subsidiary and its affiliates hold less than a 30% stake in Tianmai Biotech.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}